ALX Oncology GAAP EPS of -$0.15 misses by $0.02
- ALX Oncology press release (ALXO): Q3 GAAP EPS of -$0.15 misses by $0.02.
- Cash, cash equivalents and investments as of September 30, 2026, were $147.2 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations through the first half of 2028.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Black Friday: Create a Free Seeking Alpha Account
See what's moving the market with unlimited news access, and get 20% off your first year of any Seeking Alpha service.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.